Country for PR: China
Contributor: PR Newswire Asia (China)
Tuesday, May 24 2022 - 10:00
AsiaNet
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
BEIJING dldate May 24, 2022 /PRNewswire - AsiaNet/ --

Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals 
(Beijing) Co., Ltd. ("Biocytogen"), today announced that it will present two 
posters at the 2022 ASCO Annual Meeting, taking place in Chicago, IL and 
virtually from June 3-7, 2022. The posters describe updates from two phase I 
clinical studies in Australia for internally developed monoclonal antibodies 
(mAbs) YH003 (anti-CD40, abstract # 2603) and YH001 (anti-CTLA-4, abstract # 
2602). Both YH003 and YH001 demonstrate favorable safety and tolerability 
profiles and preliminary efficacy when administered in combination with 
anti-PD-1 mAb to patients with advanced solid tumors.

The details of the presentations are as follows:

Title 	

A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal 
antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with 
advanced solid tumors. 
(https://meetings.asco.org/abstracts-presentations/210362)

Corresponding author

Dr. Jermaine Coward

Trial

NCT04481009

Abstract number

2603

Session

Poster Session 3: Developmental Therapeutics—Immunotherapy


Title

A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal 
antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients 
with advanced solid tumors. 
(https://meetings.asco.org/abstracts-presentations/210326)

Corresponding author

Dr. Vinod Ganju

Trial

NCT04357756

Abstract number

2602

Session

Poster Session 3: Developmental Therapeutics—Immunotherapy

Both posters will be presented in-person on Sunday, June 5 from 8:00 AM–11:00 
AM CT.

About YH003

YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single 
agent or in combination with anti-PD-1 mAb drugs, YH003 demonstrated strong 
anti-tumor effects against multiple tumor models in Biocytogen's humanized CD40 
mice, without exhibiting hepatotoxicity or other toxicities. Pharmacodynamic 
studies in mice indicate that YH003 significantly increased the infiltration of 
anti-tumor T cells into tumors. Currently, YH003 is undergoing phase II 
multi-regional clinical trials (MRCTs) for the treatment of patients with 
unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC).

About YH001

YH001 is an anti-CTLA-4 monoclonal antibody. CTLA-4 is a key target for tumor 
immunotherapies, due to the potential to enhance the immune response to tumor 
cells and promote removal of regulatory T cells from the tumor 
microenvironment. Blocking the inhibitory signals from both CTLA-4 and PD-1 to 
enhance the anti-tumor responses is considered a promising tumor immunotherapy, 
as they control different types of T cells. Currently, YH001 is undergoing 
phase II MRCTs for the treatment of patients with advanced non-small cell lung 
cancer (NSCLC) and hepatocellular carcinoma (HCC). Moreover, Biocytogen/Eucure 
Biopharma has entered into a collaborative partnership agreement with TRACON 
Pharmaceuticals (NASDAQ: TCON) for the development of YH001 for multiple 
oncology indications, including soft tissue sarcoma, in North America.

About Eucure Biopharma

As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the 
mission of clinical development for Biocytogen's R&D pipelines. Relying on a 
strong clinical development team and extensive clinical development experience, 
Eucure Biopharma focuses on antibody drug therapy for oncology and other 
indications. The company has established a product pipeline for more than 10 
targets, with two products in phase II MRCT and two in phase I. For more 
information, please visit www.eucure.com (http://www.eucure.com/).

About Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology 
company that drives the research and development of novel antibody-based drugs 
with innovative technologies. Using its proprietary RenMabTM /RenLite® mouse 
platforms for fully human monoclonal and bispecific antibody development, 
Biocytogen has integrated its in vivo drug efficacy screening platforms and 
strong clinical development expertise to streamline the entire drug development 
process. Biocytogen is undertaking a large-scale project to develop antibody 
drugs for more than 1000 targets, known as Project Integrum, and has entered 
ongoing collaborations with dozens of partners worldwide to produce a variety 
of first-in-class and/or best-in-class antibody drugs. The company's pipeline 
includes 12 core products, among which two products are in phase II MRCTs and 
two products are in phase I. Headquartered in Beijing, Biocytogen has branches 
in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more 
information, please visit www.biocytogen.com (http://www.biocytogen.com/).

SOURCE:  Biocytogen

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=421880

Attachments
2022ASCO.jpg